New hope for rare blood disorder: experimental antibody EA5 enters human testing
Disease control
Recruiting now
This early-stage trial tests the safety of a new drug called EA5 in 24 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The drug is an antibody designed to block part of the immune system that attacks blood cells. The goa…
Phase: PHASE1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC